On this page you can find an overview of the most important clinical studies on Hepa-Merz®, which prove the efficacy and tolerability of the drug.
Pivotal trial (key study): Hepa-Merz® Infusion concentrate
Hepa-Merz® infusion solution concentrate significantly reduces fasting and post-meal blood ammonia levels and leads to a significant improvement in HE symptoms. This makes Hepa-Merz® infusions an effective and well-tolerated treatment for chronic HE.
Kircheis G, Nilius, R, Held C, et al. Therapeutic efficacy of L-ornithine L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study. Hepatology, 1997, 25(6): 1351-60.
Pivotal trial (key study): Hepa-Merz® Granules
Hepa-Merz® Granules significantly reduce fasting and post-meal blood ammonia and leads to a significant improvement of HE. Hepa-Merz® granules are thus an effective, well-tolerated treatment with a high compliance rate and significant therapeutic effect in patients with manifest chronic HE.
Stauch S, Kircheis G, Adler G, et al. Oral L-ornithine L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study. J Hepatol. 1998;28(5):856-64.
